I'm LongbridgeAI, I can summarize articles.Abbott Laboratories (ABT) closed the week at $102.61, up 0.65% against the S&P 500’s 0.08% decline, outperforming by roughly 0.73 percentage points. The pattern was choppy: an early push to $104.44 on Monday gave way to a low of $100.33 on Thursday, before Friday’s heavy volume lifted the stock back above $102. The weekly range was 3.97%, and the close remained below both the 20-day moving average of $108.14 and the 60-day line.
The Week
Abbott Laboratories (ABT) closed the week at $102.61, up 0.65% against the S&P 500’s 0.08% decline, outperforming by roughly 0.73 percentage points. The pattern was choppy: an early push to $104.44 on Monday gave way to a low of $100.33 on Thursday, before Friday’s heavy volume lifted the stock back above $102. The weekly range was 3.97%, and the close remained below both the 20-day moving average of $108.14 and the 60-day line. Friday’s volume expanded sharply, but the stock has yet to reclaim the shorter-term trendline.
Key Events
The infant formula settlement dominated the week. On Monday Abbott said it had reached an agreement with the US Department of Justice to resolve claims tied to the 2022 recall. Confirmation of a $384 million to $385 million payment followed on Tuesday, and the stock bounced after six straight sessions of declines. Separately, Volt, Abbott’s pulsed field ablation system for atrial fibrillation, saw its first commercial use in Canada. On Thursday the company declared its 411th consecutive quarterly dividend of $0.63 per share. A subsequent announcement detailed a per-unit dividend of R$0.18 payable on 23 November. Avricore’s HealthTab also unveiled a multi-year UK point-of-care testing deal with Abbott.
Analyst Ratings
Across 28 institutions, 18 rate the stock buy, 4 overweight, 5 hold, and 1 no opinion, with no underweight or sell ratings; the consensus rating is buy. The consensus target sits at $120.26, roughly 17.2% above the current price. Targets range from $103 to $135, a spread of about $32 that shows how divided analysts are on the pace of re-rating. Abbott ranks 6th out of 142 names in the medical devices industry.
The Week Ahead
No Abbott-specific earnings or corporate events are due. Attention turns to US macro data on Tuesday: the Richmond Fed composite index (prior 4), Wednesday’s EIA crude and Cushing inventory reports, and Thursday’s initial jobless claims (prior 196k), current account balance (prior -$226.8b), new home sales (consensus 0.608m), and natural gas inventories. These releases are unlikely to move Abbott’s fundamentals directly, but a weak claims or housing print could pressure valuations across the medical devices complex.
In Short
Abbott closed the week with the formula recall liability largely behind it, while its dividend and the Volt milestone kept a floor under sentiment. The buy-side tilt in broker ratings and the consensus target above spot point to room for upside, but the stock still trades below both the 20- and 60-day moving averages, and in the latest session both large and medium-lot flows were net sellers while small lots bought. The question for next week is whether the moving averages can start to repair without a negative surprise from US macro data.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.